Design of a Prospective, Dose-Escalation Study Evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC)
暂无分享,去创建一个
J. Grotta | J. Aronowski | M. Hossain | S. Savitz | M. Rahbar | A. Sarraj | V. Misra | A. Barreto | Loren F Shen | M. Sline | N. Sangha | Tzu-Ching Wu | N. Gonzales | P. Sahota | Miriam M. Morales | W. Hicks | J. Shah | Indrani Acosta | Xiurong Zhao | R. Khoury | M. Kasam | G. Lopez | Lenis Sosa | Rebecca Martinez | Mohammad H. Rahbar | Monir Hossain | Tzu C Wu
[1] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[2] J. Grotta,et al. 15d-Prostaglandin J2 Activates Peroxisome Proliferator-Activated Receptor-γ, Promotes Expression of Catalase, and Reduces Inflammation, Behavioral Dysfunction, and Neuronal Loss after Intracerebral Hemorrhage in Rats , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] J. Grotta,et al. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and 15d-prostaglandin J2—Mediated protection of brain after experimental cerebral ischemia in rat , 2006, Brain Research.
[4] A. Lovett-racke,et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. , 2002, Journal of immunology.
[5] D. Feinstein,et al. Peroxisome proliferator‐activated receptor‐γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type‐2 diabetic rodents , 2006, Journal of neurochemistry.
[6] R. Keep,et al. Erythrocytes and delayed brain edema formation following intracerebral hemorrhage in rats. , 1998, Journal of neurosurgery.
[7] J. Grotta,et al. Surgical treatment for intracerebral hemorrhage (STICH) , 1998, Neurology.
[8] Jun Chen,et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone , 2006, Journal of neurochemistry.
[9] O. Hurtado,et al. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] G. Landreth,et al. Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.
[11] J. Grotta,et al. Neuronal PPARγ Deficiency Increases Susceptibility to Brain Damage after Cerebral Ischemia , 2009, The Journal of Neuroscience.
[12] G. Landreth,et al. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia , 2005, Neuroscience.
[13] M. Beal,et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.
[14] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[15] J. Grotta,et al. Early presentation of hemispheric intracerebral hemorrhage , 1994, Neurology.
[16] T. Chenevert,et al. Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. , 1994, Journal of neurosurgery.
[17] S. Suga,et al. Sequential change of brain edema by semiquantitative measurement on MRI in patients with hypertensive intracerebral hemorrhage. , 1994, Acta neurochirurgica. Supplementum.
[18] B. Schürmann,et al. The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice , 2005, The Journal of Neuroscience.
[19] A David Mendelow,et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial , 2005, The Lancet.
[20] HisaoOgawa,et al. Pioglitazone Exerts Protective Effects Against Stroke in Stroke-Prone Spontaneously Hypertensive Rats, Independently of Blood Pressure , 2007 .
[21] A. Lovett-racke,et al. Peroxisome Proliferator-Activated Receptor-γ Agonist 15-Deoxy-Δ12,1412,14-Prostaglandin J2 Ameliorates Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.
[22] S. Nissen,et al. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.
[23] E. Hirsch,et al. Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.
[24] S. Mayer,et al. Treatment of intracerebral haemorrhage , 2005, The Lancet Neurology.
[25] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[26] Y. Yoshimura,et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. , 1997, Arzneimittel-Forschung.
[27] R. Keep,et al. Mechanisms of brain injury after intracerebral haemorrhage , 2006, The Lancet Neurology.
[28] M. Hüll,et al. Inflammatory mechanisms in Alzheimer's disease , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[29] J. Grotta,et al. Hematoma resolution as a target for intracerebral hemorrhage treatment: Role for peroxisome proliferator‐activated receptor γ in microglia/macrophages , 2007, Annals of neurology.
[30] J. Aronowski,et al. New Horizons for Primary Intracerebral Hemorrhage Treatment: Experience From Preclinical Studies , 2005, Neurological research.
[31] J. Greenberg,et al. A Peroxisome Proliferator-Activated Receptor-&ggr; Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia , 2005, Stroke.
[32] J T Hoff,et al. Mechanisms of Edema Formation After Intracerebral Hemorrhage: Effects of Extravasated Red Blood Cells on Blood Flow and Blood-Brain Barrier Integrity , 2001, Stroke.
[33] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[34] J. Broderick,et al. Volume of Intracerebral Hemorrhage: A Powerful and Easy‐to‐Use Predictor of 30‐Day Mortality , 1993, Stroke.
[35] T. Herdegen,et al. The intracerebral application of the PPARγ‐ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain , 2005, The European journal of neuroscience.